Literature DB >> 14671154

Abnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarism.

Henriette Mersebach1, Ole Lander Svendsen, Arne Astrup, Ulla Feldt-Rasmussen.   

Abstract

In this study of 23 hypopituitary patients and 26 healthy controls, we have addressed whether the obese state of substituted hypopituitary patients is facilitated by abnormal sympathoadrenal activity or energy expenditure (EE). All patients received adequate substitution therapy including GH therapy. The investigation program included assessment of sympathoadrenal activity (urinary catecholamines), body composition (dual-energy x-ray absorptiometry), appetite sensations (visual analog scale), and EE (indirect calorimetry in respiration chamber). Twenty-four-hour urinary epinephrine adjusted for lean body mass and fat mass was significantly lower in patients compared with controls. GH and hydrocortisone were single negative predictors of urinary epinephrine. The major determinants of EE in patients were lean body mass and fat mass, explaining 96, 95, and 80% of the variance in 24-h EE, sleeping EE, and basal metabolic rate, respectively. Addition of urinary catecholamines explained another 1-4% of the variance in 24-h EE and basal metabolic rate, respectively. Lean patients exhibited significantly more hunger than obese patients and lean controls. In conclusion, hypopituitary patients have lower sympathoadrenal activity but normal EE, compared with healthy controls. This may reflect a central defect in hypopituitarism, however the possible impact of long-term GH and hydrocortisone treatment requires further attention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671154     DOI: 10.1210/jc.2003-030870

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Mediation of the Acute Stress Response by the Skeleton.

Authors:  Julian Meyer Berger; Parminder Singh; Lori Khrimian; Donald A Morgan; Subrata Chowdhury; Emilio Arteaga-Solis; Tamas L Horvath; Ana I Domingos; Anna L Marsland; Vijay Kumar Yadav; Kamal Rahmouni; Xiao-Bing Gao; Gerard Karsenty
Journal:  Cell Metab       Date:  2019-09-12       Impact factor: 27.287

2.  Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Authors:  Kim Huynh; Marianne Klose; Kim Krogsgaard; Jørgen Drejer; Sarah Byberg; Sten Madsbad; Faidon Magkos; Abdellatif Aharaz; Berit Edsberg; Jacob Tfelt-Hansen; Arne Vernon Astrup; Ulla Feldt-Rasmussen
Journal:  Eur J Endocrinol       Date:  2022-05-09       Impact factor: 6.558

Review 3.  The use of sibutramine in the management of obesity and related disorders: an update.

Authors:  Konstantinos Tziomalos; Gerasimos E Krassas; Themistoklis Tzotzas
Journal:  Vasc Health Risk Manag       Date:  2009

4.  Thermic effect of a meal and appetite in adults: an individual participant data meta-analysis of meal-test trials.

Authors:  Anne-Marie Ravn; Nikolaj Ture Gregersen; Robin Christensen; Lone Graasbøl Rasmussen; Ole Hels; Anita Belza; Anne Raben; Thomas Meinert Larsen; Søren Toubro; Arne Astrup
Journal:  Food Nutr Res       Date:  2013-12-23       Impact factor: 3.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.